Drug Trial Radar · NCT04277624
A Study to Assess Bioequivalence of Fezolinetant Formulations in Healthy Female Participants
Last checked: Nov 20, 2026Latest source record: Oct 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
22
Actual
Start
Feb 20, 2020
Primary completion
Feb 21, 2021
Study completion Feb 26, 2021
Sponsor
- Lead sponsor
- Astellas Pharma Global Development, Inc.Astellas (ALPMY)
- Sponsor type
- Industry
- First posted
- Feb 20, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the bioequivalence of a single dose of fezolinetant test formulation compared to a single dose of fezolinetant reference formulation under fasting conditions. This study will also evaluate the safety and tolerability of a single dose of fezolinetant test formulation and a single dose of fezolinetant reference formulation.
Conditions
- Healthy Volunteers
Interventions
fezolinetant - test formulationDrug
Administered orally
fezolinetant - reference formulationDrug
Administered orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pharmacokinetics (PK) of fezolinetant in plasma: Area under the concentration-time curve (AUC) from the time of dosing extrapolated to time infinity (AUCinf)Time frame: Up to 72 hours postdose in each study period
- Pharmacokinetics (PK) of fezolinetant in plasma: Area under the concentration-time curve (AUC) from the time of dosing to the last measurable concentration (AUClast)Time frame: Up to 72 hours postdose in each study period
- Pharmacokinetics (PK) of fezolinetant in plasma: Maximum concentration (Cmax)Time frame: Up to 72 hours postdose in each study period
Locations
1 site in 1 country. Site status is shown where the registry gives one.
PAREXEL Early Phase Clinical Unit
Baltimore, Maryland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.